520 related articles for article (PubMed ID: 31276176)
1. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
2. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
3. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
Conti RM; Nikpay SS; Buntin MB
JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019.
Dickson SR; Gabriel N; Gellad WF; Hernandez I
JAMA Netw Open; 2023 Jun; 6(6):e2318145. PubMed ID: 37314806
[TBL] [Abstract][Full Text] [Related]
5. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
[TBL] [Abstract][Full Text] [Related]
6. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
7. Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance.
Robinson JC; Whaley C; Dhruva SS
N Engl J Med; 2024 Jan; 390(4):338-345. PubMed ID: 38265645
[TBL] [Abstract][Full Text] [Related]
8. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
[TBL] [Abstract][Full Text] [Related]
9. Net prices of new antiobesity medications.
Hernandez I; Sullivan SD
Obesity (Silver Spring); 2024 Mar; 32(3):472-475. PubMed ID: 38228492
[TBL] [Abstract][Full Text] [Related]
10. Specialty Drug Price Trends in the Federal 340B Drug Discount Program.
Lee CH; Chang J; McCombs J
J Manag Care Spec Pharm; 2019 Feb; 25(2):178-187. PubMed ID: 30698090
[TBL] [Abstract][Full Text] [Related]
11. Trends in Proportion of Medicare Part D Claims Subject to 340B Discounts, 2013-2020.
Dickson S; Gabriel N; Hernandez I
JAMA Health Forum; 2023 Nov; 4(11):e234091. PubMed ID: 37976048
[TBL] [Abstract][Full Text] [Related]
12. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB
JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
[TBL] [Abstract][Full Text] [Related]
13. Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
Mattingly TJ; Levy JF; Slejko JF; Onwudiwe NC; Perfetto EM
Pharmacoeconomics; 2018 Sep; 36(9):1093-1099. PubMed ID: 29752675
[TBL] [Abstract][Full Text] [Related]
14. Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.
Li Y; Xu S
JAMA Netw Open; 2022 Feb; 5(2):e220045. PubMed ID: 35179584
[TBL] [Abstract][Full Text] [Related]
15. Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments.
Arambadjis Y; Butler M; Huckfeldt P; Schondelmeyer S
Res Social Adm Pharm; 2020 Sep; 16(9):1290-1293. PubMed ID: 31147206
[TBL] [Abstract][Full Text] [Related]
16. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
[TBL] [Abstract][Full Text] [Related]
17. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
Simeone JC; Marcoux RM; Quilliam BJ
J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
[TBL] [Abstract][Full Text] [Related]
18. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
Rome BN; Feldman WB; Desai RJ; Kesselheim AS
JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
[TBL] [Abstract][Full Text] [Related]
19. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
Dusetzina SB; Conti RM; Yu NL; Bach PB
JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
[TBL] [Abstract][Full Text] [Related]
20. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
